Status:
COMPLETED
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis
Lead Sponsor:
Galderma R&D
Conditions:
Plaque-type Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a multicenter, open-label study to assess systemic plasma levels of calcitriol, calcium homeostasis and safety in adults with plaque-type psoriasis under conditions of maximized use of CD 2027...
Eligibility Criteria
Inclusion
- Diagnosis of plaque-type psoriasis involving 10% - 20% of body surface area (BSA), with a Global Severity Score of at least 3 (moderate)
Exclusion
- Other type of psoriasis (other than plaque)
- Significant abnormal lab findings
- Secondary hyperparathyroidism
- Vit D deficiency
- Hypercalcemia
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00763503
Start Date
September 1 2008
End Date
February 1 2009
Last Update
February 18 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Burke Pharmaceutical Research
Hot Springs, Arizona, United States, 71913
2
DermResearch
Austin, Texas, United States, 78759
3
J & S Studies
Bryan, Texas, United States, 77845